Gimic

ギミック

TSE Standard ・ Ticker 475A ・ Listed

Result on listing day

-5.2%

Offer price

1,150 yen

First traded price

1,090 yen

Selling 100 shares at the first traded price would have produced a loss of 6,000 yen, before fees and tax. 100 shares is the minimum trading unit in Japan.

Application period (book building): 2025-12-04 — 2025-12-09
Lottery result: 2025-12-10
Listing date: 2025-12-19
Cash needed to apply for one lot (100 shares): about 115,000 yen
Offering size (at the offer price): 2.9 billion yen ・ 2,493,400 shares
Market capitalisation at listing: 5.6 billion yen
Lock-up: Not translated — this is the wording from the Japanese offering documents, kept verbatim so it matches what your broker shows: 上位株主に180日間
Company website: https://www.gimic.co.jp/

Closing prices after listing

Compared with the first traded price of 1,090 yen.

2025-12-191,167 yen+7.1%

2025-12-221,117 yen+2.5%

2025-12-231,126 yen+3.3%

2025-12-241,133 yen+3.9%

2025-12-251,104 yen+1.3%

Brokers you can apply through

You can only enter this lottery through a broker underwriting it. The lead underwriter is Nomura Securities, which receives the largest allocation.

野村證券マネックス証券松井証券 SBI証券楽天証券みずほ証券

Broker pages are in Japanese. A comparison in English is on the brokers page.

What stands out

Cumulative interview articles with doctors passed 30,000 in September 2025, an archive that is hard for rivals to copy
In the year to March 2026 revenue rose 8.2% to 3,842 million yen and operating profit rose 70.8% to 465 million yen
The equity ratio rose from 43.7% to 73.3% thanks to the money raised at listing

What could go wrong

Operating profit is forecast to fall 35.6% to 300 million yen in the year to March 2027 because of up-front spending on advertising, hiring and development
Most of its revenue comes from Doctor's File alone, so search engine ranking changes and rival media can hit it directly
No dividend is planned for the year to March 2027 either

About the company

It runs Doctor's File, a medical information site that introduces clinics through interview articles with their doctors, and charges the listed medical institutions a monthly fee.

How it makes money

Its main product is Doctor's File, a medical information site carrying interview articles about doctors' treatment policies and personalities, and it charges the listed medical institutions a monthly fee. It also publishes Tayoreru Doctor, a regional medical magazine issued once a year per area (36 editions in the year to March 2026), and offers website production, online booking and job-change support for medical staff, but it reports a single business segment, the medical-focused platform business. Its cumulative interview articles passed 30,000 in September 2025, and Medipathy, its information-sharing app for medical institutions, was in use at 2,275 institutions as of the end of March 2026.

Where growth is meant to come from

For the year to March 2027 it plans to spend up front on advertising to raise awareness of its services, and on product development and hiring. It forecasts revenue of 4,120 million yen, up 7.2%, but operating profit of 300 million yen, down 35.6%, because of that spending. It also plans to expand in digitising clinic back-office work through Medipathy and in services that connect hospitals with clinics.

Read about this company in Japanese →

Figures are taken from the offering documents and public sources, and are checked against two independent sources before publication. Nothing here is investment advice. Shares can and do open below their offer price.